Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025 [Yahoo! Finance]
Elutia, Inc. - Class A (ELUT)
Company Research
Source: Yahoo! Finance
SILVER SPRING, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today provided a business update and financial results for the third quarter ended September 30, 2024. Business Highlights: First Commercial Use : Announced the first patient implant of EluPro, the FDA-cleared antibiotic-eluting biologic envelope for pacemakers and neurostimulators. Strong Initial Adoption : EluPro is being utilized across all major cardiac implantable electronic device (CIED) brands and in neurostimulation procedures. EluPro now accounts for 25% of BioEnvelope (CanGaroo and EluPro) sales. Robust VAC Engagement : EluPro has now been submitted to over 100 hospital system value analysis committees (VACs), with 36 accounts now actively ordering. Expanded Sales Presence : Strengthened sales team in key markets including Southern California and the Northeast, balancing direct and independent representation fo
Show less
Read more
Impact Snapshot
Event Time:
ELUT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELUT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELUT alerts
High impacting Elutia, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
ELUT
News
- Cardiac Resynchronization Therapy (CRT) Market Insights, Competitive Landscape and Market Forecast 2024-2030 [Yahoo! Finance]Yahoo! Finance
- Elutia Awarded Cardiac Rhythm Management Devices Agreement with Premier, Inc.GlobeNewswire
- Elutia Inc. (NASDAQ: ELUT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $10.00 price target on the stock.MarketBeat
- Elutia Inc (ELUT) Q3 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges [Yahoo! Finance]Yahoo! Finance
- Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025GlobeNewswire
ELUT
Sec Filings
- 12/11/24 - Form 4
- 12/11/24 - Form 4
- 12/11/24 - Form 4
- ELUT's page on the SEC website